Community Portal

A place for Clinicians and Healthcare Suppliers to share knowledge and learn more about THE CLINICIAN EXCHANGE



Provided by: Medscape

Do FMS Composite Scores Predict Subsequent Injury?

Published: Wed, 13 Dec 2017 12:00:00 EST
Is there an association between FMS composite scores and subsequent risk of injury?
British Journal of Sports Medicine

Anesthesia and Surgery During Infancy and White Matter Volume

Published: Wed, 13 Dec 2017 12:00:00 EST
Might anesthetics given during infancy have neurotoxic effects? This neuroimaging study investigated the impact of anesthesia on total and regional white matter volumes and integrity in children.

Considering Tangible Benefit for Interdependent Donors

Published: Wed, 13 Dec 2017 12:00:00 EST
The use of interdependent donors may help balance the risks and benefits of live donor transplantation.
American Journal of Transplantation

Improving the Lives of Persons With Sickle Cell Disease

Published: Wed, 13 Dec 2017 12:00:00 EST
While advances in treating and preventing the complications of sickle-cell disease have extended life expectancy, challenges remain. Two new public health efforts are working to address this.
Morbidity & Mortality Weekly Report
Displaying results 9-12 (of 20)
 1 - 2 - 3 - 4 - 5 


Bluebird and Celgene’s CAR-T hits the mark in myeloma

Published: Mon, 11 Dec 2017 12:29:31 +0000
Patients with highly advanced multiple myeloma have seen spectacular results with Bluebird Bio and Celgene’s CAR-T therapy bb2121; the disease was pushed into remission in more than half of those treated.

Gilead backs $60M Hookipa round to fund immunotherapy R&D

Published: Mon, 11 Dec 2017 11:47:59 +0000
Gilead has joined Boehringer Ingelheim and Takeda on the list of investors in Hookipa Biotech. The Big Biotech participated in a $60 million (€50 million) series C intended to equip Hookipa to advance its cytomegalovirus vaccine and cancer candidate through early clinical testing.

'Epigenetic CRISPR' edits DNA without cutting it

Published: Fri, 08 Dec 2017 20:52:28 +0000
A Salk Institute team created a form of CRISPR/Cas9 that activates specific genes without making breaks in the DNA, which can cut down on harmful side effects.

Roche uncovers clues to improving checkpoint inhibition in cancer

Published: Fri, 08 Dec 2017 17:06:36 +0000
Checkpoint inhibitors to treat cancers, such as Roche’s Tecentriq, fail to work in as many as 80% of patients—a problem that their manufacturers have been trying to solve. Now Roche is uncovering data from a Tecentriq trial in bladder cancer patients that could provide clues to countering resistance.
Displaying results 9-12 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy